WuXi Nextcode

Some of the biggest players in the life science tools and diagnostics industries including Danaher, Agilent, and Hologic presented on day two of the conference, discussing plans for 2018.

Rhythm is using WuXi's artificial intelligence capabilities to support drug development targeting pathways associated with genetic obesity syndromes.

As of this week, the project had sequenced 39,500 genomes and returned reports for about 3,000 rare disease families and more than 600 cancer patients.

With the cash, WuXi NextCode will build out its AI and deep learning, seek partnerships in precision medicine and diagnostics, and commercialize genomic tests.

The new funds will help WuXi NextCode advance and commercialize genomic tests for the Chinese market, and strengthen its position in informatics.

At the ACMG annual conference in Phoenix last week, several labs and companies discussed their efforts in healthy genome sequencing.

At the American College of Medical Genetics and Genomics annual meeting in Phoenix, WuXi presented results from a pilot study involving 190 individuals.

WuXi NextCode will integrate Geneformics' compression technology into its workflows to provide rapid, easy access to genomic datasets.

The partners will use population genomics to discover and develop novel therapeutics and companion diagnostics for a range of chronic diseases.

The company will develop a data warehouse that integrates whole-genome sequence, medical, and wearables data from patients and controls.

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.